The Market: With the market bouncing all over the place over the past couple of weeks, it's paramount to keep an eye on the public sentiment, as stocks will continue to trade along with that sentiment and not necessarily on fundamentals or material events. It's also an opportune time for shorts to take control, which could drive certain stocks with high short percentages down further than would have otherwise been the case.
It's an exciting time to go looking for deals.
CPST: Capstone Turbine has been all over the trading map this year, spiking to as high as $2-plus after a Presidential mention, but having also slipped back down to the dollar mark amid the latest round of market turmoil.
Multiple large orders and growing earnings numbers continue to have Capstone primed to play a large role in 'fueling the future', making CPST - in my opinion - a good buy once again.
This stock carried a noticeable short percentage before the market dip, which could have pushed this one down further than would have otherwise been expected. Many investors are still looking for a sure sign of pending profitability, which may also be weighing heavily on the price.
Keep an eye on it. It has been known to slip below a dollar, but it's a good bet that CPST will rebound from the current floor.
SVFC: IntelliCell BioSciences, fresh off a reverse split and name change from 'Media Exchange Group', may still be treading water just below the radar, but may be primed to make a splash in the field of regenerative medicine.
IntelliCell's process of manufacturing stromal vascular fraction containing adult adipose stem cells from adipose (fat) tissue has been assessed by some as being superior to the competition because of the use of a patented ultrasound technique, vice a chemical process.
The company continues to open multiple Adipose Stem Cell Processing Centers around the country and is looking to take advantage of the growing stem cell market.
IntelliCell's technology is being put to the test in clinical trials for multiple dermatology-related treatments, including injections for anti-aging, lines and wrinkles and acne scars, burns and treatment-related scars.
Most stocks tend to drift lower after a reverse split. With the market also slipping, SVFC could be one to watch.
TTNP.ob: Titan Pharmaceuticals will be a stock to watch this week with a pending conference call on Tuesday where the company will discuss results from the recently-completed confirmatory Phase III Probuphine trial.
Having slipped to below the $1.50 market with the market slide, Titan rebounded quickly and now trades for above $1.80 again.
Also of interest will be any comments made by management regarding a possible merger, acquisition or partnership that could provide a catalyst for the future. Speculation has been there for some time that Titan is not planning to 'go it alone' with regards to advancing Probuphine to market, and any time management speaks, investors will be paying keen attention for hints in that regard.
Titan also continues to reap 8% revenue from the Vanda (VNDA) and Novartis (NVS) Fanapt sales, although Fanapt has yet to hit the market with the force previously predicted.
The quick rebound in price of TTNP will have investors interested, although it's still yet to surpass and hold the elusive $2 mark.
One to watch.
SIRI: Back to trading for below $2, SiriusXM is well worth keeping on the watch list again. This one has bounced back and forth between being both a short and long term trade, but another round of strong earnings and growing subscribership shows that SIRI retains the potential of a long term hold.
The company is set to release a new platform within the coming quarters, and content continues to keep customers interested at a time when the service is being rolled out with over sixty percent of all new vehicles.
For Pitbull fans that like to station swap, I'd also be willing to bet that you could go hours without ever listening to anyone else other than Pitbull.
SIRI has been volatile along with the market, but volatility tends to bring investors some decent buying opportunities, and this latest slide could be just the case.
Keep an eye out for a rebound - but continue to expect volatility with this heavily-traded stock.
AMRN: Shares of Amarin have rebounded nicely from the market-dip lows over the past trading week, but are still far from the highs seen after the announcement of positive results from multiple AMR-101 trials, which were announced in succession through the late part of 2010 and early 2011.
The current billion-dollar-plus market cap might look high for a company with its main product not yet on the market, but optimism is high after the Phase III results and many believe that an eventual FDA approval is as much a shoo-in as can be assumed in this business.
That said, nothing is a shoo-in when the FDA is concerned, so risk needs to be entertained just as much as the potential rewards.
Another note worth watching is the M&A potential.
It's been discussed previously that this company has a lot of outside interest, but the CEO has also indicated that Amarin may just 'go-it-alone' with AMR-101.
A story worth watching.
Disclosure: Long TTNP, CPST.
